contact us krjpencn

뉴스현황

뉴스현황

현재 위치: > 뉴스현황

  • 08
    06

    2021

    Qing Ruan and his team examined Medicilon

    On August 4, 2021, Mr. Qing Ruan, Deputy Director of Shanghai Municipal Development and Reform Commission, and his team visited Shanghai Medicilon Inc. (Medicilon) at Chuansha Park for examination.  Professor Shuangqing Peng, CSO of Medicilon; Yaoliang Zhang, Director of the Administration Department; and Nanmei Zhou, Director of the Public Affairs accompanied the examination and organized a symposium.

  • 08
    06

    2021

    Medicilon assists SHP2 allosteric inhibitor RG001 tablet to be approved for clinical use

    Shanghai Medicilon Inc. (Medicilon) provides a range of preclinical services from drug targets to IND filing in the development of RG001 tablets to enter the clinical trial phase, including drug discovery, pharmaceutical research, and pre-clinical research (drug efficacy and safety evaluations).

  • 08
    06

    2021

    Medicilon assists Leado Pharma to obtain clinical approval for small molecule inhibitor LDS tablets

    Shanghai Medicilon Inc. (Medicilon) provided a full set of preclinical research services including pharmacokinetics and safety evaluation in the development of LDS tablets.  Medicilon successfully assisted China’s first targeted transient receptor LDS, a small molecule inhibitor of potential channels, to enter the clinical trial stage. targeting transient receptor potential channels.

  • 06
    23

    2021

    New Drugs and AI Innov Forum was successful held

    On June 18, the 12th Shanghai Medicilon symposium “New Drug + AI Innov Forum” was held in Shanghai Disneyland Hotel.  

  • 06
    07

    2021

    Medicilon assists Palaatu to obtain clinical approval for PA9159 for rhinitis

    On June 2, 2021, the National Medical Products Administration (NMPA) officially announced that the glucocorticoid drug PA9159 nasal spray was approved for clinical use. The PA9159 developed by Zhejiang Palaatu Pharmaceutical Company (Palaatu) is for seasonal and perennial allergic rhinitis.